April 30, 2020
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Chimerix Receives FDA Clearance for Rolling Submission of New Drug Applicationfor Brincidofovir as a Medical Countermeasure for Smallpox
TOKYO, Japan, April 30, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio"),which in-licensed the antiviral drug brincidofovir (BCV) from Chimerix Inc. (Headquarters: Durham,NC, "Chimerix") on September 30, 2019 and is preparing to initiate a global study of BCV, today
announced that Chimerix announced on April 28, 2020 that Chimerix has received clearance from theU.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application(NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.
Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoingcollaboration and funding provided by the Biomedical Advanced Research and Development
Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response
within the U.S. Department of Health and Human Services.
For more information, please see Chimerix’s website:
https://ir.chimerix.com/press-releases
Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated: “SymBio has theexclusive worldwide license to develop, manufacture, and commercialize BCV in all humanindications excluding the prevention and treatment of smallpox. The clearance Chimerix received tobegin the rolling submission of its NDA for BCV as a medical countermeasure for smallpox is also an
important milestone for SymBio.”1

About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating theadvancement of innovative medicines that make a meaningful impact in the lives of patients livingwith cancer and other serious diseases. Its two clinical-stage development programs are dociparstat
sodium (DSTAT) and brincidofovir (BCV).
BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For
further information, please visit the Chimerix website, www.chimerix.com.
About the Global License Agreement for Brincidofovir
SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters:Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of theagreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, andcommercialize BCV in all human indications, excluding the prevention and treatment of smallpox.
For further information, please see the SymBio’s press release dated October 1, 2019,https://www.symbiopharma.com/news/20191001.pdf
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called
SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

2